ESOPJun 5, 2026, 04:07 PM
DBV Technologies Grants CEO 4.06M PSUs Tied to Viaskin Peanut FDA Approvals
AI Summary
DBV Technologies' Board of Directors approved the 2026 Performance Share Unit Plan and granted 4,060,000 Performance Share Units (PSUs) to CEO Daniel Tassé. The vesting of these PSUs is contingent upon achieving two key performance conditions related to U.S. Food and Drug Administration (FDA) approvals for Viaskin Peanut (VP) biologics license applications. The plan aims to align long-term value with company performance and leadership continuity, with vested shares delivered in installments from July 2028 to January 2030.
Key Highlights
- DBV Technologies Board approved the 2026 Performance Share Unit Plan on June 3, 2026.
- CEO Daniel Tassé was granted 4,060,000 Performance Share Units (PSUs).
- 2,900,000 PSUs are eligible to vest upon the first FDA approval of a Viaskin Peanut BLA.
- 1,160,000 PSUs are eligible to vest upon the second FDA approval of a Viaskin Peanut BLA.
- PSUs for which performance conditions are not met by July 1, 2028, will be forfeited.
- Vested shares will be delivered in four installments from July 1, 2028, to January 1, 2030.
- Vesting is also subject to the CEO's continuous employment until July 1, 2028.
Price Impact
More from DBVT